Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis

Autor: J.Z. Lu, Xiao-ren Zhu, Min-Bin Chen, Jia-yao Zhu, Yong Yang, Yan Zhang, Ping Li, Le Wang
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Lung Neoplasms
Colorectal cancer
Squamous Cell Lung Carcinoma
Lung and Intrathoracic Tumors
0302 clinical medicine
Mathematical and Statistical Techniques
Carcinoma
Non-Small-Cell Lung
Neoplasms
Medicine and Health Sciences
Multidisciplinary
Liver Diseases
Hazard ratio
Statistics
Squamous Cell Carcinomas
Metaanalysis
Prognosis
Biliary Tract Neoplasms
030220 oncology & carcinogenesis
Physical Sciences
Medicine
Research Article
medicine.medical_specialty
Science
Gastroenterology and Hepatology
Research and Analysis Methods
Carcinomas
Large Neutral Amino Acid-Transporter 1
03 medical and health sciences
Breast cancer
Diagnostic Medicine
Internal medicine
Pancreatic cancer
Gastrointestinal Tumors
medicine
Biomarkers
Tumor
Humans
Progression-free survival
Statistical Methods
Immunohistochemistry Techniques
Survival analysis
business.industry
Cancers and Neoplasms
Hepatocellular Carcinoma
medicine.disease
Survival Analysis
Confidence interval
Non-Small Cell Lung Cancer
Pancreatic Neoplasms
Histochemistry and Cytochemistry Techniques
030104 developmental biology
Tumor progression
Immunologic Techniques
business
Mathematics
Zdroj: PLoS ONE, Vol 15, Iss 5, p e0233629 (2020)
PLoS ONE
ISSN: 1932-6203
Popis: Background The expression of the L-type amino acid transporter 1 (LAT1) plays a significant role in tumor progression. However, it remains unclear whether high LAT1 expression correlates with poor prognosis of solid tumor patients. Here, we conducted a meta-analysis to assess the potential of LAT1 in predicting the prognosis of tumor patients. Methods and findings A total of 4,579 cases were analyzed from 35 qualified studies. In patients with solid tumors, elevated expression of LAT1 is associated with poor prognosis (overall survival [OS]: pooled hazard ratio (HR) = 1.848, 95% confidence interval (CI) = 1.620–2.108, P < 0.001; disease free survival [DFS]: pooled HR = 1.923, 95% CI = 1.585–2.333, P < 0.001; progression free survival [PFS]: pooled HR = 1.345, 95% CI = 1.133–1.597, P = 0.001). Furthermore, in subgroup analysis, we found an association between high LAT1 expression and poor OS in non-small cell lung cancer (HR = 1.554, 95% CI = 1.345–1.794, P < 0.001), pancreatic cancer (HR = 2.052, 95% CI = 1.613–2.724, P < 0.001) and biliary tract cancer (HR = 2.253, 95% CI = 1.562–3.227, P < 0.001). Conclusion The results of this meta-analysis indicate the reliability and potential of using LAT1 expression as a predictive biomarker in solid cancers prior to treatment. However, further studies with larger sample sizes would be beneficial for fully evaluating the predictive value of LAT1 expression for clinical applications.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje